Meritage Portfolio Management Has $1.74 Million Stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Meritage Portfolio Management increased its stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 8.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 48,181 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,886 shares during the quarter. Meritage Portfolio Management owned about 0.09% of Supernus Pharmaceuticals worth $1,742,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of SUPN. Stephens Investment Management Group LLC boosted its position in Supernus Pharmaceuticals by 1.8% in the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock valued at $60,246,000 after buying an additional 33,710 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Supernus Pharmaceuticals by 29.9% during the third quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock valued at $54,655,000 after acquiring an additional 403,028 shares during the period. Geode Capital Management LLC boosted its holdings in Supernus Pharmaceuticals by 5.3% in the third quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock valued at $46,218,000 after acquiring an additional 74,438 shares during the last quarter. Victory Capital Management Inc. increased its position in Supernus Pharmaceuticals by 1.1% in the third quarter. Victory Capital Management Inc. now owns 742,871 shares of the specialty pharmaceutical company’s stock worth $23,163,000 after purchasing an additional 7,833 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Supernus Pharmaceuticals by 14.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 712,395 shares of the specialty pharmaceutical company’s stock worth $22,212,000 after purchasing an additional 91,354 shares during the period.

Supernus Pharmaceuticals Trading Down 1.3 %

Shares of SUPN opened at $39.48 on Thursday. The stock has a market cap of $2.18 billion, a P/E ratio of 36.90 and a beta of 0.90. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The stock’s 50-day moving average price is $37.29 and its two-hundred day moving average price is $34.69.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.25. The business had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. Supernus Pharmaceuticals’s revenue for the quarter was up 14.2% on a year-over-year basis. During the same period last year, the company posted ($0.29) EPS. As a group, equities analysts forecast that Supernus Pharmaceuticals, Inc. will post 2.38 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Cantor Fitzgerald started coverage on shares of Supernus Pharmaceuticals in a research note on Monday, January 6th. They issued an “overweight” rating and a $57.00 target price on the stock. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insiders Place Their Bets

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total transaction of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at $402,915.30. The trade was a 48.29 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 9.30% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.